Han Xu, MD/PhD/FAPCR
Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701
Emerging Leaders
not ranked
Current Leaders
#2948 pts
All-Time Leaders
not ranked
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2023. 4 trials as lead/chair. How it works →
Trials led — by scientific impact
Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.
Phase 2ActiveHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
0
impact
Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS
Phase 3ActiveHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
0
impact
Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxicity in Patients With Prostate Cancer.
Phase 2ActiveHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
0
impact